In contrast to the HER2 aptamers identified (Table 3), the HB5 aptamer was only investigated for its targeted drug delivery system and was not radiolabelled to investigate its nuclear medical imaging specificity for HER2 BC detection and diagnosis [46]. Here, ERBB2 is linked to breast cancer.